Enhanced Pilocarpine Formulations with Optimized Buffer Characteristics for Improved Stability and Efficacy

The present inventive concept relates to novel pilocarpine formulations with modified buffer characteristics, resulting in improved stability, shelf life, and efficacy for treating ophthalmic conditions such as presbyopia.

The original patent disclosed pilocarpine formulations with reduced buffer content, but limitations remained, including potential degradation and instability. The present inventive concept addresses these limitations by introducing optimized buffer characteristics, ensuring enhanced stability and efficacy.

The inventive concept involves modifying the buffer characteristics of pilocarpine formulations to maintain a pH range of between about 3.5 and about 5.5, thereby increasing the shelf life and stability of the formulation. Additionally, the introduction of chelating agents and antioxidants can further enhance the stability of the pilocarpine compound. The formulations can be manufactured with viscosity-enhancing agents to improve ease of administration.

The present inventive concept introduces novel buffer characteristics and additives that significantly improve the stability and efficacy of pilocarpine formulations, distinguishing it from the original patent. The optimized pH range and the use of chelating agents and antioxidants provide a non-obvious solution to the limitations of the original patent.

Alternative embodiments of the inventive concept could include varying the type and concentration of chelating agents, antioxidants, and viscosity-enhancing agents. Additionally, the formulations could be adapted for different ophthalmic conditions or administration routes.

The enhanced pilocarpine formulations have significant commercial potential in the ophthalmic industry, particularly for treating presbyopia. The improved stability and efficacy of the formulations could lead to increased market share and revenue for Somerset Therapeutics, LLC.